Intellia Therapeutics(DE:38I)
€9.87-0.45 (-4.36%)
DE:38I
Intellia Therapeutics stock forecast
€9.87
At close:-0.45 (-4.36%)
Intellia Therapeutics (38I) Stock Forecast & Price Target
14 Followers
38I Analyst Ratings
Hold
4Buy5Hold2Sell
Based on 11 analysts giving stock ratings to Intellia Therapeutics in the past 3 months
38I Stock 12 Month Forecast
Average Price Target
€17.36▲(75.84% Upside)Based on 11 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is EUR 17.36 with a high forecast of EUR 44.29 and a low forecast of EUR 7.23. The average price target represents a 75.84% change from the last price of EUR 9.87.
Past 12 Months12 Month ForecastJan2026Oct2026
High€44.29
Average€17.36
Low€7.23
Highest Price TargetHighest€44.29Average Price Target€17.36Lowest Price TargetLowest€7.23
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Mitchell Kapoor | H.C. Wainwright | €22.60 | buy | 128.96%Upside | Reiterated | 11/13/26 | ||
| Whitney Ijem | Canaccord Genuity | €44.29 | buy | 348.76%Upside | Reiterated | 11/09/26 | ||
| Brian Cheng | J.P. Morgan | €7.23→€8.14 | sell | -17.57%Downside | Assigned | 11/09/26 | ||
| Alec Stranahan | Bank of America Securities | €15.37→€14.46 | hold | 46.53%Upside | Reiterated | 11/06/26 | ||
| Terence Flynn | Morgan Stanley | €13.56 | hold | 37.38%Upside | Reiterated | 11/06/26 | ||
| Debanjana Chatterjee | JonesTrading | €26.21→€24.41 | buy | 147.28%Upside | Reiterated | 11/06/26 | ||
| David Nierengarten | Wedbush | €11.75 | hold | 19.06%Upside | Reiterated | 11/06/26 | ||
| Luca Issi | RBC Capital | €13.56 | hold | 37.38%Upside | Reiterated | 11/05/26 | ||
| Derek Archila | Wells Fargo | €13.56 | hold | 37.38%Upside | Reiterated | 10/15/26 | ||
| Eliana Merle | Barclays | €7.23 | sell | -26.73%Downside | Initiated | 10/07/26 | ||
| Joseph Thome | TD Cowen | ― | buy | ― | Reiterated | 09/04/26 | ||
| Jonathan Miller | Evercore ISI | €14.46→€21.69 | buy | 119.80%Upside | Upgraded | 08/07/26 | ||
| Myles Minter | William Blair | ― | buy | ― | Reiterated | 08/06/26 | ||
| Salveen Richter | Goldman Sachs | €8.14 | sell | -17.57%Downside | Reiterated | 08/06/26 | ||
| Andy Chen | Wolfe Research | €8.14 | sell | -17.57%Downside | Downgraded | 07/15/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Mitchell KapoorH.C. Wainwright | BuyReiterated€22.60 | 11/13/26 | 128.96%Upside | ||
| Whitney IjemCanaccord Genuity | BuyReiterated€44.29 | 11/09/26 | 348.76%Upside | ||
| Brian ChengJ.P. Morgan | SellAssigned€7.23→€8.14 | 11/09/26 | -17.57%Downside | ||
| Alec StranahanBank of America Securities | HoldReiterated€15.37→€14.46 | 11/06/26 | 46.53%Upside | ||
| Terence FlynnMorgan Stanley | HoldReiterated€13.56 | 11/06/26 | 37.38%Upside | ||
| Debanjana ChatterjeeJonesTrading | BuyReiterated€26.21→€24.41 | 11/06/26 | 147.28%Upside | ||
| David NierengartenWedbush | HoldReiterated€11.75 | 11/06/26 | 19.06%Upside | ||
| Luca IssiRBC Capital | HoldReiterated€13.56 | 11/05/26 | 37.38%Upside | ||
| Derek ArchilaWells Fargo | HoldReiterated€13.56 | 10/15/26 | 37.38%Upside | ||
| Eliana MerleBarclays | SellInitiated€7.23 | 10/07/26 | -26.73%Downside | ||
| Joseph ThomeTD Cowen | BuyReiterated | 09/04/26 | ― | ||
| Jonathan MillerEvercore ISI | BuyUpgraded€14.46→€21.69 | 08/07/26 | 119.80%Upside | ||
| Myles MinterWilliam Blair | BuyReiterated | 08/06/26 | ― | ||
| Salveen RichterGoldman Sachs | SellReiterated€8.14 | 08/06/26 | -17.57%Downside | ||
| Andy ChenWolfe Research | SellDowngraded€8.14 | 07/15/26 | -17.57%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Intellia Therapeutics
3 Months
Success Rate14/39 ratings generated profit
36%
Average Return
+4.67%
Copying Mani Foroohar's trades and holding each position for 3 Months would result in 35.90% of your transactions generating a profit, with an average return of +4.67% per trade.
1 Year
Success Rate7/22 ratings generated profit
32%
Average Return
-2.52%
Copying Joon Lee's trades and holding each position for 1 Year would result in 31.82% of your transactions generating a profit, with an average return of -2.52% per trade.
2 Years
Success Rate3/16 ratings generated profit
19%
Average Return
-16.80%
Copying Debanjana Chatterjee's trades and holding each position for 2 Years would result in 18.75% of your transactions generating a profit, with an average return of -16.80% per trade.
38I Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 5 | 5 | 5 |
| Buy | 4 | 3 | 2 | 2 | 1 |
| Hold | 10 | 7 | 5 | 6 | 7 |
| Sell | 4 | 3 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 23 | 19 | 14 | 15 | 15 |
In the current month, 38I has received 6 Buy Ratings, 7 Hold Ratings, and 2 Sell Ratings. 38I average Analyst price target in the past 3 months is 17.36.
38I Financial Forecast
High€-0.37
Consensus€-0.71
Low€-0.90
38I Earnings Forecast
Next quarter’s earnings estimate for 38I is -EUR 0.71 with a range of -EUR 0.90 to -EUR 0.37. The previous quarter’s EPS was -EUR 0.81. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€62.8M
Consensus€12.3M
Low€6.27M
38I Sales Forecast
Next quarter’s sales forecast for 38I is EUR 12.31M with a range of EUR 6.27M to EUR 62.76M. The previous quarter’s sales results were EUR 6.41M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
38I Stock Forecast FAQ
What is DE:38I’s average 12-month price target, according to analysts?
Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is €17.36.
What is DE:38I’s upside potential, based on the analysts’ average price target?
Intellia Therapeutics has 75.84% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Intellia Therapeutics a Buy, Sell or Hold?
Intellia Therapeutics has a consensus rating of Hold, which is based on 4 buy ratings, 5 hold ratings and 2 sell ratings.
What is Intellia Therapeutics’s share price target?
The average share price target for Intellia Therapeutics is €17.36. This is based on 11 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €44.29, and the lowest forecast is €7.23. The average share price target represents a 75.84% increase from the current price of €9.87.
What do analysts say about Intellia Therapeutics?
Intellia Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Street analysts.
How can I buy shares of Intellia Therapeutics?
To buy shares of DE:38I, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
